Clinical Study
Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
Figure 2
IFX therapy promotes intestinal mucosal healing in CD patients. Representative endoscopic photographs are demonstrated from a patient in remission group (a, b), a patient from response group (c, d), and a patient from failure group (e, f) before (a, c, and e) and 10 weeks after IFX treatment (b, d, and f).
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |